T-cell lymphoma cell lines (HUT102 and HUT78) established at the National Cancer Institute: History and importance to understanding the biology, clinical features, and therapy of cutaneous T-cell lymphomas (CTCL) and adult T-cell leukemia-lymphomas (ATLL)

Journal of Cellular Biochemistry

Volumn 62, Issue SUPPL. 24, 1996, Pages 12-23

  Bunn Jr , Paul A ^b   Foss, Francine M ^a  

^a BOSTON UNIVERSITY   (United States)

^b NONE

Author keywords

CTCL; HIV; HTLV 1; IL 2; Sezary

Indexed keywords

CELL LINE; CLINICAL FEATURE; ERYTHRODERMA; HELPER CELL; HUMAN; HUMAN CELL; KARYOTYPE; LYMPH NODE BIOPSY; LYMPHOMA CELL; MYCOSIS FUNGOIDES; PHENOTYPE; PRIORITY JOURNAL; RETROVIRUS; REVIEW; SCREENING; SEZARY SYNDROME; T CELL LYMPHOMA; VIRUS CHARACTERIZATION; ADULT; AGED; B CELL LYMPHOMA; BIOSYNTHESIS; CELL CULTURE; CUTANEOUS T CELL LYMPHOMA; GENE EXPRESSION REGULATION; GENETICS; HEALTH CARE ORGANIZATION; HISTORY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PATHOLOGY; PREVALENCE; PROTO ONCOGENE; SKIN TUMOR; T CELL LEUKEMIA; UNITED STATES; VIROLOGY;

HTLV; HUMAN T-LYMPHOTROPIC VIRUS 1; UNIDENTIFIED RETROVIRUS;

ANTINEOPLASTIC ANTIMETABOLITE; BIOLOGICAL RESPONSE MODIFIER; CYTOKINE; CYTOKINE RECEPTOR; MONOCLONAL ANTIBODY; TUMOR PROTEIN;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL RESPONSE MODIFIERS; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTORY, 20TH CENTURY; HIV; HIV INFECTIONS; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; LEUKEMIA, T-CELL, ACUTE; LYMPHOMA, AIDS-RELATED; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASM PROTEINS; PREVALENCE; PROTO-ONCOGENES; RECEPTORS, CYTOKINE; SEZARY SYNDROME; SKIN NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR CELLS, CULTURED; UNITED STATES;

EID: 0029679582     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.240630503     Document Type: Review

References (125)

1. Alibert JLM (1806): Description des maladies de la peau; observees a l'Hospital St. Louis. Paris: Barrois L'aine et Fils.
2. Epstein EH Jr, Levin DL, Croft JD Jr, et al. (1972): Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings. Medicine 15:61-72.
3. Levi JA, Wiernik PH (1975): Management of mycosis fungoides: Current status and future prospects. Medicine 54:73-88.
4. Sézary A, Bouvrain Y (1938): Erythrodermie avec presence de cellules monstrueuses dans le derme et dans le sang circulant. Bull Soc Fr Dermatol Syph 45:254-260.
5. Crossen PE, Mellor JEL, Finley AG, et al. (1971): The Sézary Syndrome cytogenetic studies and identification of the Sézary cell as an abnormal lymphocyte. Am J Med 50:24-34.
6. Lutzner M, Edelson R, Schein P, et al. ( 1975): Cutaneous T-eell lymphomas: The Sézary Syndrome mycosis fungoides and related disorders. Am Int Med 83:534-552.
7. Brouet JC, Flandrin G, Seligmann M (1975): Indications of the thymus derived mature of the proliferative cells in six patients with the Sézary Syndrome. N Engl J Med 289:341-344.
8. Broder S, Edelson RL, Lutzner MA, et al. (1976): The Sézary syndrome. A malignant proliferation of helper T cells. J Clin Invest 58:1297-1306.
9. Edelson RL, Raafat J, Berger CL, Grossman M, Troyer C, Hardy M (1979): Antithymocyte globulin in the management of cutaneous T-cell lymphoma. Cancer Treat Rep 63:675-680.
10. Edelson RL, Iacktor M, Andrews A, et al (1974): Successful management of the Sézary Syndrome: Mobilization and removal of extracutaneous neoplastic T-cells by leukapheresis. N Engl J Med 291:293-294.
11. Shackney SE, Edelson R, Bunn PA Jr (1979): The kinetics of Sezary cell production. Cancer Treat Rep 63:659-661.
12. Bunn PA, Jr, Edelson RL, Ford SS, Shackney SE (1981): Patterns of cell proliferation and migration in patients with the Sezary syndrome. Blood 57:452-463.
13. Bunn PA, Jr, Huberman MS, Whang-Peng J, Schechter GP, Guccion JG, Matthews MJ, Gazdar AF, Dunnick NR, Fischmann AB, Ihde DC, Cohen MH, Fossieck BE Jr, Minna JD (1980): Prospective staging evaluation of patients with cutaneous T-cell lymphomas: Demonstration of a high frequency of extracutaneous dissemination. Ann Int Med 93:223-230.
14. Sausville EA, Worsham GF, Matthews MJ, Makuch RW, Fischmann AB, Schlechter GP, Gazdar AF, Bunn PA Jr (1985): Histologie assessment of lymph nodes in mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma): Clinical correlations and prognostic import of a new classification system. Hum Pathol 16: 1098-1109.
15. Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M, Minna JD, Glatstein E, Ihde DC, Kaye F, Veach SR, Gazdar AF, Phelps R, O'Connor T, Trepel JB, Cotelingham J, Bunn PA, Jr (1988): Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary Syndrome: Definition of three distinctive prognostic groups. Ann Int Med 109:372-382.
16. Bunn PA Jr, Whang-Peng J, Carney DN, Schlam ML, Knutsen T, Gazdar AF (1980): Correlation of DNA content analysis by flow cytometry and cytogenetic analysis in mycosis fungoides and Sezary syndrome: Diagnostic and prognostic implications. J Clin Invest 65:1440-1448.
17. Schechter GP, Bunn PA Jr, Fischmann AB, Matthews MJ, Guccion J, Soehnlen F, Munson D, Minna JD (1979): Blood and lymph node T lymphocytes in cutaneous T-cell lymphomas: Evaluation by light microscopy. Cancer Treat Rep 63:571-574.
18. Schechter GP, Sausville E, Fischmann BA, Soehnlen F, Eddy J, Matthews MA, Munson D, Makuch R, Bunn PAJr (1987): Evaluation of circulating malignant cells provides prognostic information in cutaneous T-cell lymphoma. Blood 69:841-849.
19. Guccion JG, Fischmann BA, Bunn PA Jr, Schechter GP, Patterson RH, Matthews MJ (1979): The ultrastructural appearance of cutaneous T-cell lymphomas in skin, lymph nodes and peripheral blood. Cancer Treat Rep 63:565-570.
20. Whang-Peng J, Bunn PA Jr, Knutsen T, Schechter GP, Gazdar AF, Matthews MJ, Minna JD (1979): Cytogenetic abnormality in patients with cutaneous T-cell lymphomas. Cancer Treat Rep 63:575-580.
21. Whang-Peng J, Bunn PA Jr, Knutsen T, Matthews MJ, Schechter GP, Minna JD (1982): Clinical implications of cytogenetic studies in cutaneous T-cell lymphoma. Cancer 50:1539-1553.
22. Haynes BF, Bunn PA Jr, Mann D, Thomas C, Eisenbarth GS, Minna JD, Fauci AS (1981): Cell surface differentiation antigens of the malignant T cell in Sezary syndrome and mycosis fungoides. J Clin Invest 67:523-530.
23. Haynes BI, Metzgar RS, Minna JD, Bunn PA Jr (1981): Phenotypic characterization of cutaneous T-cell lymphoma: Comparison with other malignant T cells with the use of monoclonal antibodies. N Engl J Med 304: 1319-1323.
24. Bertness V, Kirsch I, Hollis G, Johnson B, Bunn PA Jr (1985): T-cell receptor gene rearrangements are clinical markers of human T-cell lymphomas. N Engl J Med 313:534-538.
25. Carney DN, Bunn PA Jr, Scheehter GP, Gazdar AF (1980): Lymphocyte transformation in patients with cutaneous T-cell lymphomas. Intl J Cancer 26:534-542.
26. Gazdar AF, Carney DN, Russell EK, Schechter GP, Bunn PA Jr (1979): In vitro growth of cutaneous T-cell lymphomas. Cancer Treat Rep 63:587-590.
27. Gazdar AF, Carney DN, Bunn PA Jr, Russell EK, Scheehter GP, Guccion JG (1980): Mitogen requirements for the in vitro propagation of cutaneous T cell lymphomas. Blood 55:409-417.
28. Chen T (1992): Karyotypic derivation of H9 cell line expressing human immunodeficiency virus susceptibility. JNCI 84:1922-26.
29. Bunn P, Whang-Peng J, Gazdar A, Minna J, Carney D (1993): Karyotype derivation of H9 cell line (letter). JNCI 85:1168-70.
30. Blayney DW, Jaffe ES, Blattner WA, Cossman J, Robert-Guroff M, Longo D, Bunn PA Jr, Gallo RC (1983): The human T-cell leukemia/lymphoma virus associated with American adult T-cell leukemia/lymphomas (ATL). Blood 62:401-405.
31. Bunn PA Jr, Schechter GP, Blayney D, Young RC, Matthews MJ, Blattner W, Broder S, Robert-Guroff M, Gallo RC (1983): Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. N Engl J Med 309:257-264.
32. Broder S, Bunn PA Jr, Jaffe ES, Blattner WA, Gallo RC, Wong-Staal F, Waldmann TA DeVita VT (1984): T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Int Med 100:543-557.
33. Brigham BA, Bunn PA Jr, Horton JE, Schechter GP, Wahl LM, Bradley EC, Dunnick NR, Matthews MJ (1982): Skeletal manifestations in cutaneous T-cell lymphomas. Arch Dermatol 118:461-467.
34. Dodd RC, Winkler CF, Bunn PA Jr, Williams ME, Gray TK (1986): Calcitriol levels in hypercalcemic patients with adult T-cell lymphoma. Arch Intern Med 146:1971-1972.
35. Jaffe ES, Blattner WA, Blayney DW, Bunn PA Jr, Robert-Guroff M, Gallo RC (1984): The pathologic spectrum of HTLV associated leukemia/lymphoma in the United States. Am J Surg Pathol 8:263-275.
36. Wano Y, Uchiyama T, Kukui K, Maeda M, Uchino H, Yodoi J (1984): Characterization of human interleukin-2 receptor (tac antigen) in normal and leukemic T-cells: Co-expression of normal and aberrant receptors on Hut-102 cells. J Immunol 132:3005-3010.
37. Gootenberg JE, Ruscetti FW, Mier JW, Gazdar AF, Gallo RC (1981): Human cutaneous T-cell lymphoma and leukemia cell lines produce and respond to T-cell growth factor. J Exp Med 154:1403-1405.
38. Rho H, Poiesz BJ, Ruscetti FW, Gallo RC (1981): Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology 112:355-359.
39. Poiesz BJ, Ruscetti FM, Gazdar AF, Bunn PA Jr, Minna JD, Gallo RC (1980): Detection and isolation of type-C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77:7415-7419.
40. Posner LE, Guroff MR, Kalyanaraman VS, Poiesz BJ, Ruscetti FW, Bunn PA Jr, Minna JD, Gallo RC (1981): Natural antibodies to the human T-cell lymphoma virus in patients with cutaneous T-cell lymphomas. J Exp Med 154:333-346.
41. Kalyanaraman VS, Sarngadharan MG, Bunn PA Jr, Minna JD, Gallo RC (1981): Antibodies in human sera reactive against an internal structural protein of human T-cell lymphoma virus. Nature 294:271-273.
42. Gallo RC, Kalyanaraman VS, Sarngadharan MG, Sliski A, Vonderheid EC, Maeda M, Nakao Y, Yamada K, Ito Y, Gutensohn N, Murphy S, Bunn PA Jr, Catovsky D, Greaves MF, Blayney D, Blattner W, Jarrett WFH, zur Hausen H, Seligmann M, Brouet JC, Haynes BF, Jegasothy BV, Jaffe E, Cossman J, Broder S, Fisher RI, Golde, DW, Robert-Guroff M (1983): Association of human type C retrovirus with a subset of adult T-cell cancers Cancer Res 43:3892-3899.
43. Robert-Guroff M, Kalyanaraman VS, Blattner WA, Popovic M, Sangadharan MG, Maeda M, Blayney D, Catovsky D, Bunn PA Jr, Shibita A, Nakao Y, Ito Y, Aoki T, Gallo RC (1983): Evidence for HTLV-infection of family members of HTLV positive T-cell leukemia-lymphoma patients. J Exp Med 157:248-258.
44. Blayney DW, Blattner WA, Robert-Guroff MR, Jaffe E, Fisher RI, Bunn PA Jr, Patton MG, Rarick HR, Gallo RC (1983): The human T-cell leukemia/lymphoma virus (HTLV) in the Southeastern United States. JAMA 250:1048-1052.
45. Schupbach J, Sarngadharan MG, Blayney DW, Kalyanaraman VS, Bunn PA Jr, Gallo RC (1984): Demonstration of vial antigen p24 in circulating immune complexes of two patients with human T-cell leukemia/ Iymphoma virus (HTLV) positive Iymphoma. Lancet 1:302-304.
46. Uchiyama T, Yodoi J, Sagawa K, et al (1977): Adult T-cell leukemia: Clinical and hematological features of 16 cases. Blood 50:481-492.
47. Catovsky D, Greaves MF, Rose M, et al (1982): Adult T-cell lymphoma-leukemia in blacks from the West Indies. Lancet 1:639-643.
48. Whang-Peng J, Bunn PA Jr, Knutsen T, Kao-Shan CS, Broder S, Gelman E, Jaffe ES, Blattner W, Lofters W, Young RC, Gallo RC (1985): Cytogenetic studies in human T-cell Iymphoma virus (HTLV)-positive leukemia-lymphoma in the United States. J Natl Cancer Inst 74:357-369.
49. Sadamori N, Nishino K, Kusano M, et al (1986): Significance of chromosome 14 anomaly at band 14q11 in Japanese patients with adult T-cell leukemia. Cancer 58:2244-2250.
50. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K (1984): Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA 81:2534.
51. Yamaguchi K, Seiki M, Yoshida M, Nishimura H, Kawano F, Takatsuki K (1984): The detection of human T cell leukemia virus proviral DNA and its application for classification and diagnosis of T cell malignancy. Blood 63:1235.
52. Fleming AF, Maharajan R, Abraham M, Kulkami AG, Bhusnurmath SR, Okpara RA, Williams E, Akinsete I, Schneider J, Bayer H, Hunsmann G (1986): Antibodies to HTLV-I in Nigerian blood-donors, their relatives and patients with leukaemias, lymphomas and other diseases. Int J Cancer 38:809.
53. Sandler SG (1986): HTLV-I and HTLV-II: New risks for recipients of blood transfusions? JAMA 256:2245-2246
54. Takatsuki K, Yamaguchi K, Kawan F, et al (1985): Clinical diversity in adult T-cell leukemia-lymphoma. Cancer Res (Suppl) 45:4644-4645.
55. Erlich GD, Han T, Bettigole R, et al (1988): Human T-lymphotropic virus type I-associated benign transient immature T-cell lymphocytosis. Am J Hematol 27:49-55.
56. Jacobsen S, Raine CS, Mingioli ES, et al (1988): Isolation of an HTLV-I like retrovirus from patients with tropical spastic paraparesis. Nature 311:540-543.
57. Popovic M, Sarngadharan M, Read E, Gallo R (1984): Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and Pre-AIDS. Science 224:497-500.
58. Gallo R, Salahuddin S, Popovic M, Shearer G, Kaplan M, Haynes B, Palker T, Redfield R, Oleske J, Safai B, White G, Foster P, Markham P (1984): Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224:500-502.
59. Schupbach J, Popovic M, Gilden R, Gonda M, Sarngadharen M, Gallo R (1984): Serological analysis of a subgroup of human T-lymphotrophic retroviruses (HTLV111) associated with AIDS. Science 224:503-505.
60. Sarngadharan M, Popovic M, Bruch L, Schupbach J, Gallo R (1984): Antibodies reactive with human T-lymphotrophic viruses (HTLV111) in serum of patients with AIDS. Science 224:506-508.
61. Popovic M, Read-Connole E, Gallo R (1984): T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet 1472-73.
62. Mann D, O'Brien S, et al (1989): Origin of the HIV-susceptible CD4+ cell line H9. AIDS Res Human Retroviruses 5:253
63. Rubinstein E (1990): The untold story of HUT78. Science 248:1499-1507.
64. Yahi N, Fantini J, Baghdiguian S, Chermann J ( 1991): Human T-lymphoblastoid cells selected for growth in serum-free media provide new tools for study of HIV replication and cytopathogenicity. J Virol Methods 34: 193-207.
65. Brenner C, Tam A, Nelson P, Engleman E, Suzuki N, Fry K, Larrick J (1989): Message amplification phenotyping: A technique to simultaneously measure multiple mRNAs from small numbers of cells. Biotechniques 7:1096-1103.
66. Holter W, Kalthoff R, Majdic O, Knapp W (1993): Interleukin-4 production by the malignant cell line HUT78. Lymphokine Cytokine Res 12:33-8.
67. Fukudome K, Furuse M, Fukuhara N, Orita S, Imai T, Takagi S, Nagira M, Hinuma Y, Yoshie O (1992): Strong induction of ICAM-1 in human T-cells transformed by human T-cell leukemia virus type 1 and depression of ICAM-1 or LFA-1 in adult T-cell leukemia derived cell lines. Intern J Cancer 52:418-27.
68. Hsu S, Tseng C, Hsu P (1990): Expression of p55 (TAC) interleukin-2 receptor but not p75 IL2R in cultures H-RS cells and H-RS cells in tissues. Am J Pathol 136:735-44.
69. Dalloul A, Laroche L, Bagot M, Mossalayi D, Fourcade C, Thacker D, Hogge D, Merle-Beral H, Debre P, Schmitt C (1992): Interleukin-7 is a growth factor for Sezary lymphoma cells. J Clin Invest 90:1054-60.
70. Foss F, Koc Y, Stetler-Stevenson M, Nguyen D, O 'Brien M, Turner R, Sausville E (1994): Co-stimulation of cutaneous T-cell lymphoma cells by IL7 and IL2 : Potential autocrine or paracrine effectors in the Sezary syndrome. J Clin Oncol 12:326-335.
71. Armitage R, Ziegler S, Friend D, Park L, Fanslow W (1992): Identification of a novel low affinity receptor for human interleukin-7. Blood 79:1738-45.
72. Veillette A, Bookman M, Horak E, Bolen J (1988): The CD4 and CD8 cell surface antigens are associated with the internal membrane tyrosine protein kinase p561ck. Cell 55:301-8
73. Samelson L, Phillips A, Luong E, Klausner R (1990): Association of the fyn protein-tyrosine kinase with the T-cell antigen receptor. Proc Natl Acad Sci USA 87: 4358-4362.
74. Yananashi Y, Mori S, Yoshida M, Kishimoto T, Inoue K, Yamamoto T, Toyoshima K (1989): Selective expression of a protein-tyrosine kinase, p56 lyn in hematopoietic cells and association with production of human T-cell lymphotrophic virus type I. Proc Natl Acad Sci 86:6538-42.
75. Blake T, Langdon W (1992): A rearrangement of the c-abl proto-oncogene in HUT78 T-lymphoma cells results in a truncated protein. Oncogene 7:757-62.
76. Finger L, Huebner K, Cannizzaro L, McLeod K, Nowell P, Croce C (1988): Chromosomal translocation in T-cell leukemia line HUT78 results in a MYC fusion transcript. Proc Nat Acad Sci USA 85(23):9158-62.
77. Petroni D, Comi P, Giglioni B, Stacchini A, Martinotti G, Guerrasio A, Saglio G (1992): Tumorigenic activity of a rearranged c-myc gene from a human T-cell leukemia cell line. Carcinogenesis 13:883-5.
78. Cheng J, Haas M (1990): Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10:5502-5509.
79. Waldmann TA, Goldman CK, Bongiovanni KF, et al (1988): Therapy of patients with human T-cell lymphotropic virus I-induced adult T-cell leukemia with anti-tac, a monoclonal antibody to the receptor for interleukin-2. Blood 72:1805-1816.
80. Krenke M, Depper J, Leenard WJ, et al (1985): Adult T-cell leukemia: A potential target for ricin A chain immunotoxins. Blood 65:1416-1421.
81. Fitzgerald M, Waldmann T, Willingham MC, et al (1984): Pseudomonas exotoxin-anti-tac: Cell specific immunotoxin active against cells expressing the T-cell growth factor receptor. J Clin Invest 74:966-971.
82. Kozack RW, Atcher RW, Gasow OA, et al (1986): Bismuth-212 labeled anti-tac monoclonal antibody: Alpha particle emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci USA 83:474-478.
83. Rosolen A, Nakanishi M, Poplack D, Cole D, Quinines R, Reaman G, Cotelingam J, Trepel J, Sausville E, Marti G, Neckers L, Colamonici O (1989): Expression of interleukin-2 receptor beta subunit in hematopoietic malignancies. Blood 73:1968-72.
84. Nasu K, Said J, Vonderheid E (1985): Immunopathology of cutaneous T-cell lymphomas. Am J Pathol 199: 436-7.
85. Abel E, Lindae M, Hoppe R, Wood G (1988): Benign and malignant forms of erythroderma: Cutaneous immunophenotypic characteristics. J Am Acad Derm 19: 1089-95.
86. Kung E, Meissner K, Loning T (1988): Cutaneous T-cell lymphoma: Immunocytochemical study on activation/proliferation and differentiation associated antigens in lymph nodes, skin, and peripheral blood. Virchows Arch A Pathol Anat 413:539-49.
87. Williams D, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom T, Murphy J (1987): Diphtheria toxin receptor binding domain substitution with interleukin-2: Genetic reconstruction and properties of a diphtheria toxin related interleukin-2 fusion protein. Protein Eng 1:493-498.
88. Bacha P, Williams D, Waters C, Murphy J, Strom T (1988): Interleukin-2 receptor mediated action of a diphtheria toxin related interleukin-2 fusion protein. J Exp Med 167:612-622.
89. Waters C, Schimke P, Snider C, Strom T, Murphy J (1990): Receptor binding requirements for entry of a diphtheria toxin-related interleukin-2 fusion protein into cells. Eur J Immunol 20:785-791.
90. Williams D, Snyder C, Strom T, Murphy J (1990): Structure/function analysis of interleukin-2 toxin (DAB486IL2). J Biol Chem 285:11885-11889.
91. LeMaistre CF, Meneghetti C, Rosenblum M, Reuben J, Shaw J, Deisseroth A, Woodworth T, Parkinson D (1992): Phase I trial of an interleukin-2 fusion toxin (DAB 486IL2) in hematologic malignancies expressing the IL-2 receptor. Blood 79:2547-2554.
92. LeMaistre CF, Craig F, Meneghetti C, McMullin B, Parker K, Reuben J, Boldt D, Rosenblum M, Woodworth T (1993): Phase I trial of a 90-minute infusion of the fusion toxin DAB(486)IL2 in hematologic cancers. Cancer Res 53:3930-34.
93. Hesketh P, Caguioa P, Koh H, Dewey H, Facada A, McCaffrey R, et al (1993): Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol 11:1682-1690.
94. Seragen 1993 Quarterly Report, November 22, 1993. Hopkington, MA: Seragen, Inc.
95. Kiyokawa T, Shirono K, Hattori T, et al (1989): Cytotoxicity of interleukin-2 toxin toward lymphocytes from patients with ATLL. Cancer Res 49:4042-4046.
96. Sidi Y, Edwards NL, Winkler C, Bunn PA Jr, Mitchell BS (1985): Differential metabolism of deoxyribonucleosides by leukaemic T-cells of immature and mature phenotype. Br J Haematol 61:125-134.
97. Dearden C, Matutes E, Catovsky D (1991): Deoxycoformycin in the treatment of mature T-cell leukaemias. Br J Cancer 64:903-906.
98. Cummings FJ, Kim K, Neiman RS, Comis RL, Oken MM, Weitzman SA, et al (1991): Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 9:565-571.
99. Thaler J, Kuse R, Willemze R, et al (1988): Deoxycoformycin in therapy of refractory lymphoid neoplasms. Onkologic 11:35-37.
100. Grever MR, Bisaccia E, Scarborough DA, Mertz EN, Neidhart JA (1983): An investigation of 2′-Deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 62:279-282.
101. Kanofsky JR, Roth DG, Smyth J, Baron JM, Sweet DL, Ultmann JE (1982): Treatment of lymphoid malignancies with 2′-deoxycoformycin: A pilot study. Am J Clin Oncol 5:179-183.
102. O'Dwyer PJ, Wagner B, Leyland-Jones B, Wittes RE, et al (1988): 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies. Ann Int Med 108:733-743.
103. Dang-Vu AP, Olsen EA, Vollmer RT, Greenberg ML, Hershfield MS (1988): Treatment of cutaneous T-cell lymphoma with 2′-deoxycoformycin (pentostatin). J Am Acad Dermatol 19:692-698.
104. Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ (1990): Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group Study. J Natl Cancer Inst 82:1353-1355.
105. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1992): 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80: 587-592.
106. Kuzel TM, Samuelson E, Roenigk HH Jr, Torp E, Rosen ST (1992): Phase II trial of 2 chlorodeoxyadenosine for the treatment of mycosis fungoides or the Sézary syndrome. Proc Am Soc Clin Oncol 11:A1089 (abstract).
107. Lofters W, Campbell M, Gibbs N, Cheson B (1987): 2′ deoxycoformycin therapy in adult T-cell leukemia/ lymphoma. Cancer 60:2605-2608.
108. Tingsgaard P, Jorgensen H, Vejlsgaard GL (1993): Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol 51:63-72.
109. Foss FM, Ihde DC, Breneman DL, Phelps RM, et al (1992): Phase II study of pentostatin and intermittent high-dose interferon alfa-2a in advanced mycosis fungoides/Sézary Syndrome. J Clin Oncol 10:1907-1913.
110. Bunn PA Jr, Foon KA, Ihde DC, Longo DL, Eddy J, Winkler et al (1984): Recombinant leukocyte A interferon: An active agent in advanced cutaneous T-cell lymphomas. Ann Int Med 101:484-487.
111. Foon KA, Roth MS, Bunn PA Jr (1987): Interferon therapy of non-Hodgkin's Lymphoma, Cancer 59(Suppl):601-604.
112. Kohn EC, Steis RG, Sausvilie ET, et al (1990): Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome. J Clin Oncol 8:155-160.
113. Kaplan EH, Rosen ST, Norris DB, Roenigk HH Jr, Saks SR, Bunn PA Jr (1990): Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82:208-212.
114. Kuzel TM, Gilyon K, Springer E, Variakojis D, Kaul K, Bunn PA Jr, et al (1990): Interferon Alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82:203-207.
115. Kaye FJ, Bunn PA Jr, Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al (1989): A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New Engl J Med 321:1784-1790.
116. Miller RA, Levy R (1981): Response of cutaneous T-cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet II:226-230.
117. Bunn PA Jr, Norris DA (1990): The therapeutic role of interferons and monoclonal antibodies in cutaneous T-cell lymphomas. J Invest Dennatol 95(Suppl):209S-212S.
118. Bertram JH, Gill PS, Levine AM, Boquiren D, et al (1986): Monoclonal antibody T101 in T-cell malignancies: A clinical pharmacokinetic and immunologic correlation. Blood 68:752-761.
119. Dillman RO, Shawler DL, Dillman JB, Royston I (1984): Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881-891.
120. 125I-labeled monoclonal antibody T101 in human malignant T-cell lines. Blood 67:429-435.
121. 111In-T101 monoclonal antibody. New Engl J Med 315:673-680.
122. Carrasquillo JA, Mulshine JL, Bunn PA Jr, Reynolds JC, Foon KA, Schroff RW, et al (1987): Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med 28:281-287.
123. 111In-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. Cancer Res 47:6093-6099.
124. 131I-labeled monoclonal antibody: An Illinois Cancer Council study. J Clin Oncol 5:562-573.
125. LeMaistre CF, Rosen S, Frankel A, Kornfeld S, Saria E, Meneghetti C, et al (1991): Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 78:1173-1182.